Last reviewed · How we verify
Dexamethasone Sodium Phosphate (dexamethasone phosphate)
At a glance
| Generic name | dexamethasone phosphate |
|---|---|
| Sponsor | Merck & Co. |
| Drug class | Corticosteroid |
| Target | Androgen receptor, Glucocorticoid receptor, Mineralocorticoid receptor |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
| First approval | 1959 |
Approved indications
- Primary or secondary adrenocortical insufficiency
- Acute adrenocortical insufficiency
- Shock unresponsive to conventional therapy
- Congenital adrenal hyperplasia
- Nonsuppurative thyroiditis
- Hypercalcemia associated with cancer
- Post-traumatic osteoarthritis
- Synovitis of osteoarthritis
- Rheumatoid arthritis
- Acute and subacute bursitis
- Epicondylitis
- Acute nonspecific tenosynovitis
- Acute gouty arthritis
- Psoriatic arthritis
- Ankylosing spondylitis
- Systemic lupus erythematosus
- Acute rheumatic carditis
- Pemphigus
- Severe erythema multiforme (Stevens-Johnson Syndrome)
- Exfoliative dermatitis
Common side effects
- Congestive heart failure
- Osteoporosis
- Vertebral compression fractures
- Aseptic necrosis of femoral and humeral heads
- Pathologic fracture of long bones
- Peptic ulcer with possible subsequent perforation and hemorrhage
- Pancreatitis
- Ulcerative esophagitis
- Impaired wound healing
- Steroid myopathy
- Loss of muscle mass
- Hypokalemic alkalosis
Key clinical trials
- Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia (PHASE2)
- A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia (PHASE3)
- CB-839 HCl in Combination With Carfilzomib and Dexamethasone in Treating Patients With Recurrent or Refractory Multiple Myeloma (PHASE1)
- Comparing the Combination of Selinexor-Daratumumab-Velcade-Dexamethasone (Dara-SVD) With the Usual Treatment (Dara-RVD) for High-Risk Newly Diagnosed Multiple Myeloma (PHASE2)
- Testing the Investigational Medication Combination of Teclistamab and Pomalidomide Compared to the Usual Treatment (Carfilzomib, Pomalidomide, and Dexamethasone) for Patients With Multiple Myeloma Who Have Relapsed Shortly After Treatment (PHASE1,PHASE2)
- Combination Chemotherapy With or Without Donor Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia (PHASE2)
- Testing the Investigational Medication Combination of Daratumumab and Teclistamab Compared to the Usual Treatment (Daratumumab, Pomalidomide, Dexamethasone or Daratumumab, Carfilzomib, Dexamethasone) for Patients With High-risk Multiple Myeloma Refractory or in First Relapse (PHASE2)
- Testing the Use of Steroids and Tyrosine Kinase Inhibitors With Blinatumomab or Chemotherapy for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia in Adults (PHASE3)
Patents
| Patent | Expiry | Type |
|---|---|---|
| 10028965 | 2034-05-23 | Method of Use |
| 8563027 | 2030-02-12 | Method of Use |
| 12144889 | 2041-04-26 | Method of Use |
| 12150896 | 2036-10-07 | Method of Use |
| 11097061 | 2039-06-23 | Formulation |
| 10022502 | 2034-06-22 | Method of Use |
| 11458041 | 2037-11-16 | Method of Use |
| 11304961 | 2037-12-18 | Formulation |
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
| FDA Orange Book | Patents + exclusivity |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Dexamethasone Sodium Phosphate CI brief — competitive landscape report
- Dexamethasone Sodium Phosphate updates RSS · CI watch RSS
- Merck & Co. portfolio CI